ArticleDrug design, development and therapy2025
Impact of Remimazolam on Postoperative Delirium in Elderly Non-Cardiac Surgery Patients Admitted to the ICU: A Retrospective Propensity Score Matched Study.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Safety and efficacy of remimazolam in critical illness.Journal of intensive care · 2026Review
- Effect of Remimazolam on Postoperative Delirium in Elderly Surgical Patients: A Critical Review of Pharmacological Mechanisms and Clinical Evidence.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative delirium (POD) is a common complication. Remimazolam, a novel ultra-short-acting benzodiazepine, has been introduced in anesthesia practice, but its impact on the incidence of POD remains unclear. This study aims to evaluate the association between intraoperative use of remimazolam and the incidence of POD. Methods: In this retrospective cohort study, patients aged 65 years and older who underwent elective non-cardiac surgery and were directly transferred to the ICU postoperatively were included. Based on intraoperative use of remimazolam, patients were categorized into the remimazolam group or the non-remimazolam group. The primary outcome was the incidence of POD within seven days postoperatively or until discharge (whichever occurred first), assessed using the CAM-ICU or the 3D-CAM. Propensity score matching (PSM) and multivariable logistic regression analyses were performed to adjust for potential confounders. Results: After PSM, 826 pairs of patients were analyzed. The overall incidence of POD was 10.29%. The incidence of POD was 9.32% in the remimazolam group and 11.26% in the non-remimazolam group ( Conclusion: In elderly patients undergoing non-cardiac surgery, intraoperative use of remimazolam was not significantly associated with the incidence of postoperative delirium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.